At RESI, You Can Make New International Connections with Investors and Scientist Entrepreneurs

By Karen Deyo, Investor Research Analyst, LSN

Over a third of registered attendees for RESI on June 4th come from firms based outside the US. That’s an incredible audience for any early stage life science entrepreneur or investor who is looking to broaden their network and make new international connections in the global early stage life science world.

RESI’s international attendees include both startups and investors. With RESI’s afternoon track on Asia-North America Partners, LSN has seeded a venue where international connections can be made, and on June 4th RESI will be a source for both international investors and also global life science discoveries.

Life science startups from around the world have applied to the Innovation Challenge, representing countries such as Canada, France, Taiwan, and also including a large delegation from South Korea sponsored by KOTRA. Other startups attending RESI come from as far away as Australia, Argentina and Denmark.

The investors attending RESI are also from all around the world, including countries such as Malaysia, Japan and Germany. International attendees include family offices, venture capital firms, venture philanthropists and large strategic partners from across the word.
Attending RESI is a great way to meet and connect with the international life sciences community, both for companies looking to form relationships with investors and for investors looking to identify new and exciting technologies.

RESI 101: What Is RESI, What’s the Format, and Who Can You Meet There?

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The Redefining Early Stage Investments (RESI) Conference Series is an ongoing conference series of 5 events across North America for early stage life sciences companies to source investors, create relationships, and eventually, get funding.  If you’ve never been to RESI, there’s a lot to take in.  In this article we’ll cover who you can meet at RESI, what happens throughout the day, and how RESI’s format maximizes your chance of making connections.

The RESI conference focuses on the diverse breadth of early stage investors that Life Science Nation (LSN) tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

The RESI Partnering Forum allows fundraising executives to identify and book up to 16 meetings with life science investors who fit their company’s technology sector and stage of development. Because RESI is a pure partnering conference the “ad hoc” meeting component is critical as the conference is arranged so that it is easy to network and investors and strategic partners have red ribbons on their badges which facilitates introductions with the scientist-entrepreneurs and fundraising CEOs who are at RESI to meet them.

Attendees, through an expansive series of panels and workshops, have the chance to hear first-hand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.

Event format

RESI provides wrap around conference content, daylong matchmaking and networking. While the matchmaking focuses on 1 to 1 meetings and appointment setting, it is different than other similar investor events. No one is hosted. The companies that seek funding pay to attend. The investment organizations are invited to attend at no cost. As the partnering system will match the buyers and sellers together based on fit there is no guesswork as to who is selling to who which is a common problem at other events where partnering is an afterthought.

RESI Innovation Challenge: The Innovation Challenge takes place at every RESI conference and is a huge hit with early stage global investors seeking firms that align with their investment mandates. It was created for scientist-entrepreneur or fundraising CEOs starting to accumulate compelling proof-of-concept animal data or early stage clinical data. LSN has developed an expert system that facilitates the quick scoring and ranking of all of the companies and their technology assets that apply to get into the Innovation Challenge. A typical RESI conference gets over 100+ applications and LSN vets and ranks the top 30 applicants who present their technologies in an exhibition-style format throughout the full-day conference. Presenters gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5 to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors.

Attendees

Funding seekers – CEOs and senior executives from life science organizations, and scientist-entrepreneurs who have invented potentially valuable technology assets.

Investors – ten categories of early stage investors and strategic channel partnerships in life science or healthcare including

  • Investment staff involved directly in an early stage life science or healthcare venture capital or private equity fund.
  • Investment staff at a family office or private wealth fund that invests in life sciences.
  • External innovation, early stage partnering or in-licensing staff from major corporations in the lifescience and healthcare industry.
  • Active life science angels or executive staff at angel organizations that invest in early stage life science companies.
  • Investment staff and executives at nonprofit organizations, venture philanthropy/impact investment firms or patient groups that provide funding to startup companies.
  • Senior management or investment staff from a pension, endowment, foundation or employee benefit plan currently invested in life sciences.

Exhibitors –

  • Scientific and technical service providers looking for early stage start-ups: CROs, CMOs.
  • Business service providers: accounting, consulting, law firms.
  • Regional life science organizations: incubators, accelerators, state government, bio-clusters.

Insights from Genomics Investors Panelists

By Jessica Yang, Investor Research Analyst, LSN

During RESI on MaRS – as part of Toronto Health Innovation Week – we invited five panelists from renowned investment groups focusing on genomics to share their insights. How do they assess the genomics-related areas of investment?

Moderated by Ihor Boszko, Vice President, Business Development, Ontario Genomics, the Genomics Investor Panelists were:

Here are some takeaway points from the panel discussion:

Tools, platforms, and technologies
Q: What do you see as exciting opportunities on the platforms/tools side of genomics? Is it in the decentralization of sequencing? Other genomics technologies?

  1. The key is to think about what kinds of applications and markets these companies are targeting. When investors look at new sequencing platforms, they are thinking about what differentiates these new technologies from centralized sequencing – what can these platforms do that centralized sequencing cannot? For innovative genomics companies, they must identify their target markets and specific applications they want to address in the decentralized models.
  2. From different angles, all points to the same direction – the guiding principle of making investments in the healthcare arena is looking for unique and differentiated technologies that address unmet needs. The other is costs, anything expanding access while lowering the cost speaks to investor’s interests. For example, platform technologies that make things cheaper, better, or faster, making it practical in clinical settings – this is what the investors are looking for.

Direct-to-consumer in Genomics

Q: What do you think about direct-to-consumer products in Genomics?

  1. More and more direct-to-consumer products come out on the market, and it’s getting easier for everyone to do it. However, genetics and genomics are complicated. In the current healthcare system, most people aren’t trained to order or interpret the results. The challenge is that training and sophistication will lag behind the technology for computers.

Some of these direct-to-consumer tasks are negatively impacting their reputation as it relates to quality. One of the ethics dilemmas around direct-to-consumer products is that people don’t understand the terms and conditions, and some of that is companies selling consumer data,

Hot Investor Mandate 4: Venture Arm of Large Korean Corporate Invests in Digital Health, with Increased Interests in Investment Opportunities in Biotech Therapeutics

A venture capital arm of a large Korean corporate has several offices in the USA. The firm has approximately has invested over $200M in 40 companies in the last year and invested $100M in 20 companies in 2016. The investment size greatly varies, depending on the opportunity. The firm is actively seeking new investment opportunities in the life sciences and will look globally.

The firm invests in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The firm is also interested in therapeutics, particularly synthetic biology, nanotechnology, and gene therapy. The firm is opportunistic in terms of stage of development.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI 2018 Investor Footprint

By Chris Cummings, Senior Marketing Manager, LSN

We are expecting significant international attendance at RESI Boston this June, due to its proximity to the BIO International Convention. Over 100 investors are already registered! The conference will be the third RESI of 2018, and is sure to continue matching early-stage investors with Biotech, Medtech, Diagnostics, and Digital Health startups. Check out some of the stats below to see what has happened so far at RESIs in 2018…


Click Here to See Investors

RESI Boston Summer: Agenda Announced

By Lucy Parkinson, VP of Investor Research, LSN

BIO Week 2018 starts on June 4th, and it will be a busy time for all of us in the Boston life science scene.  RESI aims to kick off the week with a full day of partnering and focused content for early stage entrepreneurs who are looking for financing and strategic relationships.  RESI Boston Summer will feature new panels on Investment Opportunities in the Microbiome, Investing In Oncology Innovation, and Investing In Mental & Behavioral Health, as well as the return of RESI’s focused discussions on Family Offices, Venture Philanthropy, Big Pharma and many other topics that span the gamut of life science investment and technology.  With an international crowd heading to Boston for the busy conference week, the Asia-North America track will provide access to advice from experienced international delegates.  We hope you can join us on June 4th.

 

Life Science Nation’s Redefining Early Stage Investments (RESI) Conference Series Changed the Game – Here’s How.

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation’s Redefining Early Stage Investments (RESI) conference series is unique in several ways:

  • The Innovation Challenge that takes place at every RESI conference is a huge hit with early stage global investors seeking firms that align with their investment mandates.  LSN developed an expert system that facilitates the quick scoring and ranking of all of the companies and their technology assets that apply to get into the Innovation Challenge. A typical RESI conference gets over 100+ applications and LSN vets and ranks the top 30 applicants.
  • RESI is held every few months at major innovation hubs and gives both fundraising CEOs, early-stage investor/partners and service providers a capability to use RESI as part of their ongoing yearly business and partnering activities. Scientist/entrepreneurs can weave themselves into the RESI conference series and dramatically increase face time with prime partnering targets. The ability to carry on a dialogue every few months greatly aids in transmitting the latest information and cultivating the relationships.
  • RESI is one of the very few healthcare conferences that is cross-domain, in that it features Biotech, Medtech, Diagnostics and Digital Health. Many investors have multiple investment mandates covering multiple silos in the life science arena.
  • RESI is primarily a powerful  partnering conference using a unique profile-based partnering system that will have up to 1400 meetings between buyers and sellers in one day. LSN has integrated a matching algorithm in our partnering software that connects the right investors/partners with the right early stage companies that are a fit for stage of development and product set. I think if you polled some of your colleagues they would say that RESI is a well-known partnering vehicle and attest to the dynamic nature of a RESI event.

The importance of continued dialog in maintaining partner relationships is specifically why LSN chose to incorporate a RESI conference every couple of months throughout the year.  RESI partnering has produced compelling results – over 350 firms have raised close to 500 million by using RESI as part of an ongoing fundraising vehicle.

LSN presently has 5 RESI conferences a year – JP Morgan (during), Toronto (part of Health Innovation Week), Summer BIO (day before), Boston (September) and NYC (November). The long-term goal is to expand RESI to China, Europe and South America and thus have a one-of-a-kind ongoing global event.